Programs – Our Pipeline

Zyngenia Inc. has applied its technology to generate a pipeline comprised of innovative multi-specific and multi-valent biotherapeutics (Zybodies™) that address well-validated targets. Zyngenia Inc. has advanced three programs into preclinical development and achieved preclinical proof-of-concept with both bi-specific and tri-specific Zybodies in inflammation and cancer.